Hepatic encephalopathy: An update of pathophysiologic mechanisms

Proceedings of the Society for Experimental Biology and Medicine

Volumn 222, Issue 2, 1999, Pages 99-112

  Hazell, Alan S ^a   Butterworth, Roger F ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMMONIA; BENZODIAZEPINE RECEPTOR; GLUTAMATE AMMONIA LIGASE; GLUTAMATE TRANSPORTER; LIVER ENZYME; MANGANESE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CATECHOLAMINE RELEASE; ENERGY METABOLISM; HEPATIC ENCEPHALOPATHY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACRANIAL PRESSURE; NEUROTRANSMISSION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; SHORT SURVEY;

EID: 0032694105     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1373.1999.d01-120.x     Document Type: Short Survey

References (161)

1. Norenberg MD. The astrocyte in liver disease. Adv Cell Neurobiol 2:303-352, 1981.
2. Butterworth RF, Giguère JF, Michaud J, Lavoie J, Layrargues GP. Ammonia: Key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 6:1-12, 1987.
3. Lavoie J, Giguère JF, Layrargues GP, Butterworth RF. Activities of neuronal and astrocytic marker enzymes in autopsied brain tissue from patients with hepatic encephalopathy. Metab Brain Dis 2:283-290, 1987.
4. B in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Brain Res 621:349-352, 1993.
5. Lavoie J, Layrargues GP, Butterworth RF. Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. Hepatology 11:874-878, 1990.
6. Lockwood AH, Yap EW, Rhoades HM, Wong WH. Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J Cereb Blood Flow Metab 11:331-336, 1991.
7. Lockwood AH, Murphy BW, Donnelly KZ, Mahl TC, Perini S. Positron-emission tomographic localization of abnormalities of brain metabolism in patients with minimal hepatic encephalopathy. Hepatology 18:1061-1068, 1993.
8. O'Carroll RE, Hayes PC, Ebmeier KP, Dougall N, Murray C, Best JJ, Bouchier IA, Goodwin GM. Regional cerebral blood flow and cognitive function in patients with chronic liver disease. Lancet 337:1250-1253, 1991.
9. Posner MI, Driver J. The neurobiology of selective attention. Curr Opin Neurobiol 2:165-169, 1992.
10. Cruz NF, Duffy TE. Local cerebral glucose metabolism in rats with chronic portacaval shunts. J Cereb Blood Flow Metab 3:311-320, 1983.
11. Audet R, Butterworth RF. Portacaval anastomosis results in more severe neurological impairment and more widespread reductions in cerebral metabolism in old versus young adult rats: Implications for post-TIPS encephalopathy. Metab Brain Dis 13:69-78, 1998.
12. Brown SW, Clarke MA, Tomlin PI. Fatal liver failure following generalized tonic-clonic seizures. Seizure 1:75-77, 1992.
13. Traber PG, DalCanto M, Ganger DR, Blei AT. Electron microscopic evaluation of brain edema in rabbits with galactosamine-induced fulminant hepatic failure: Ultrastructure and integrity of the blood-brain barrier. Hepatology 7:1272-1277, 1987.
14. Kato MD, Hughes RD, Keays RT, Williams R. Electron microscopic study of brain capillaries in cerebral edema from fulminant hepatic failure. Hepatology 15:1060-1066, 1992.
15. Eck NV. Ligature of the portal vein. Voen Med J St. Petersburg (Russ) 130:1-2, 1877.
16. Gabuzda D Jr, Philips GB, Davidson CS. Reversible toxic manifestations in patients with cirrhosis of the liver given cation-exchange resins. N Engl J Med 246:124-130, 1952.
17. Butterworth RF. Pathophysiology of hepatic encephalopathy: The ammonia hypothesis revisited. In: Bengtsson F, Ed. Progress in Hepatic Encephalopathy and Metabolic Nitrogen Exchange. Boca Raton, FL: CRC Press, pp9-24, 1991.
18. Lockwood AH, Yap EW, Wong W-H. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 11:337-341, 1991.
19. Raabe WA. Neurophysiology of ammonia intoxication. In: Butterworth RF, Layrargues GP, Eds. Hepatic Encephalopathy: Pathophysiology and Treatment. Clifton, NJ: Humana Press, pp49-77, 1989.
20. Fan P, Lavoie J, Le NL, Szerb JC, Butterworth RF. Neurochemical and electrophysiological studies on the inhibitory effect of ammonium ions on synaptic transmission in slices of rat hippocampus: Evidence for a postsynaptic action. Neuroscience 37:327-334, 1990.
21. Szerb JC, Butterworth RF. Effect of ammonium ions on synaptic transmission in the mammalian central nervous system. Prog Neurobiol 39:135-153, 1992.
22. Levin LH, Koehler RC, Brusilow SW, Jones J, Traystman RJ. Elevated brain water during urease-induced hyperammonemia in dogs. In: Hoff JT, Betz AL, Eds. Intracranial Pressure. Berlin: Springer-Verlag, pp1032-1034, 1989.
23. Takahashi H, Koehler RC, Brusilow SW, Traystman RJ. Inhibition of brain glutamine accumulation prevents cerebral edema in hyperammonemia in rats. Am J Physiol 281:H826-H829, 1991.
24. Ganz R, Swain M, Traber P, CalCanto M, Butterworth RF, Blei AT. Ammonia-induced swelling of rat cerebral cortical slices: Implications for the pathogenesis of brain edema in acute hepatic failure. Metab Brain Dis 4:213-223, 1989.
25. Blei AT, Traber PG. Brain edema in experimental fulminant hepatic failure. In: Butterworth RF, Layrargues GP, Eds. Hepatic Encephalopathy: Pathophysiology and Treatment. Clifton, NJ: Humana Press, pp231-244, 1989.
26. Voorhies TM, Ehrlich ME, Duffy TE, Petito CK, Plum F. Acute hyperammonemia in the young primate: Physiologic and neuropathologic correlates. Pediatr Res 17:970-975, 1983.
27. Norenberg MD, Baker L, Norenberg LO, Blicharska J, Bruce-Gregorios JH, Neary JT. Ammonia-induced astrocyte swelling in primary culture. Neurochem Res 16:833-836, 1991.
28. Blei AT, Olafsson S, Themen G, Butterworth RF. Ammonia-induced brain edema and intracranial hypertension in the rats after portacaval anastomosis. Hepatology 19:1437-1444, 1994.
29. van Gelder NM. Metabolic interactions between neurons and astroglia: Glutamine synthetase, carbonic anhydrase, and water balance. In: Jasper HH, van Gelder NM, Eds. Basic Mechanisms of Neuronal Hyperexcitability. New York: Alan R. Liss, pp5-29, 1983.
30. Record CO, Buxton B, Chase R, Curzon G, Murray-Lyon IM, Williams R. Plasma and brain amino acids in fulminant hepatic failure and their relationship to hepatic encephalopathy. Eur J Clin Invest 6:387-394, 1976.
31. 1H-NMR spectroscopy in cerebral cortex of the rat during acute hepatic encephalopathy. In: Bengtsson F, Jeppson B, Almdal T, Vilstrup H, Eds. Progress in Hepatic Encephalopathy and Metabolic Nitrogen Exchange. Boca Raton, FL: CRC Press, pp197-209, 1991.
32. Lai JC, Cooper AJ. Brain α-ketoglutarate dehydrogenase: Kinetic properties, regional distribution and effects of inhibitors. J Neurochem 47:1376-1386, 1986.
33. Hindfelt B, Plum F, Duffy TE. Effects of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts. J Clin Invest 59:386-396, 1977.
34. Therrien G, Giguère JF, Butterworth RF. Increased cerebrospinal fluid lactate reflects deterioration of neurological status in experimental portal-systemic encephalopathy. Metab Brain Dis 6:225-231, 1991.
35. Yao H, Sadoshima S, Fujii K, Kusada K, Ishitsuka T, Tamaki K, Fujishima M. Cerebrospinal fluid lactate in patients with hepatic encephalopathy. Eur Neurol 27:182-187, 1987.
36. Kulisevsky J, Pujol J, Balauzo J, Junqué C, Deus J, Capdevilla A, Villanueva C. Pallidal hyperintensity on magnetic resonance imaging in cirrhotic patients: Clinical correlations. Hepatology 16:1382-1388, 1992.
37. Spahr L, Butterworth RF, Fontaine S, Bui L, Therrien G, Millette P, Lebrun L-H, Zayed J, Leblanc A, Layrargues GP. Increased blood manganese in cirrhotic patients: Relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology 24:1116-1120, 1996.
38. Weissenborn K, Ehrenheim C, Hori A, Kubicka S, Manns MP. Pallidal lesions in patients with liver cirrhosis: Clinical and MRI evaluation. Metab Brain Dis 10:219-231, 1995.
39. Inoue E, Hori S, Narumi I, Fujita M, Kuriyama K, Kadota T, Kuroda C. Portal-systemic encephalopathy: Presence of basal ganglia lesions with high signal intensity on MR images. Radiology 179:551-555, 1991.
40. Butterworth RF, Spahr L, Fontaine S, Layrargues GP. Manganese toxicity, dopaminergic dysfunction, and hepatic encephalopathy. Metab Brain Res 10:259-267, 1995.
41. Papavasiliou PS, Miller ST, Cotzias GC. Role of liver in regulating distribution and excretion of manganese. Am J Physiol 211:211-216, 1966.
42. Versieck J, Barbier F, Speecke A, Hoste J. Manganese, copper, and zinc concentrations in serum and packed blood cells during acute hepatitis, chronic hepatitis, and posthepatic cirrhosis. Clin Chem 20:1141-1145, 1974.
43. Hauser RA, Zesiewicz TA, Rosemurgy AS, Martinez C, Olanow CW. Manganese intoxication and chronic liver failure. Ann Neurol 36:871-875, 1994.
44. Devenyi AG, Barron TF, Mamourian AC. Dystonia, hyperintense basal ganglia, and high whole blood manganese levels in Alagille's syndrome. Gastroenterology 106:1068-1071, 1994.
45. 1-weighted MR images in patients receiving parenteral nutrition. Radiology 181:177-120, 1991.
46. Nelson K, Golnick J, Korn T, Angle C. Manganese encephalopathy: Utility of early magnetic resonance imaging. Br J Ind Med 50:510-513, 1993.
47. Layrargues GP, Spahr L, Butterworth RF. Increased manganese concentrations in pallidum of cirrhotic patients. Lancet 345:735, 1995.
48. Krieger D, Krieger S, Jansen O, Gass P, Theilmann L, Lichtnecker H. Manganese and chronic hepatic encephalopathy. Lancet 346:270-274, 1995.
49. Rose C, Butterworth RF, Zayed J, Spahr L, Huet PM, Gareau L, Layrargues GP. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and impaired hepatobiliary elimination. Hepatology 26:182A, 1997.
50. Newland MC, Ceckler TL, Kordower JH, Weiss B. Visualizing manganese in the primate basal ganglia with magnetic resonance imaging. Exp Neurol 106:251-258, 1989.
51. Hazell AS, Norenberg MD. Manganese decreases glutamate uptake in cultured astrocytes. Neurochem Res 22:1443-1447, 1997.
52. Hazell AS, Desjardins P, Butterworth RF. Increased expression of glyceraldehyde-3-phosphate dehydrogenase in cultured astrocytes following exposure to manganese. Neurochem Int 35:11-17, 1999.
53. Aschner M, Gannon M, Kimelberg HK. Manganese uptake and efflux in cultured rat astrocytes. J Neurochem 58:730-735, 1992.
54. Pentschew A, Ebner F, Kovatch R. Experimental manganese encephalopathy in monkeys: A preliminary report. J Neuropathol Exp Neurol 22:488-499, 1963.
55. McCandless DW, Schenker S. Effect of acute ammonia intoxication on energy stores in the cerebral reticular-activating system. Exp Brain Res 44:325-330, 1981.
56. Norenberg MD. Hepatic encephalopathy: Studies with astrocyte cultures. In: Norenberg MD, Hertz L, Schousboe A, Eds. The Biochemical Pathology of Astrocytes. New York: Alan R. Liss, Inc., pp451-464, 1988.
57. 31P nuclear magnetic resonance study. J Neurochem 53:102-110, 1989.
58. 31P magnetic resonance spectroscopy in patients with chronic hepatic encephalopathy. Hepatology 20:1173-1178, 1994.
59. Lavoie J, Giguère J-F, Layrargues GP, Butterworth RF. Amino acid changes in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. J Neurochem 49:692-697, 1987.
60. Girard G, Butterworth RF. Portacaval anastomosis results in region-selective loss of glutamine synthetase in brain. Metab Brain Dis 8:207-215, 1993.
61. Knecht K, Michalak A, Rose C, Rothstein JD, Butterworth RF. Decreased glutamate transporters (GLT-1) expression in frontal cortex of rats with acute liver failure. Neurosci Lett 229:201-203, 1997.
62. Schmidt W, Wolf G, Grungreiff K, Meier M, Reum T. Hepatic encephalopathy influences high affinity uptake of transmitter glutamate and aspartate into the hippocampal formation. Metab Brain Dis 5:19-32, 1990.
63. Butterworth RF, Le O, Lavoie J, Szerb JC. Effect of portacaval anastomosis on electrically stimulated release of glutamate from rat hippocampal slices. J Neurochem 56:1481-1484, 1991.
64. Moroni F, Lombardi G, Moneti G, Cortesini C. The release and neosynthesis of glutamic acid are increased in experimental models of hepatic encephalopathy. J Neurochem 40:850, 1983.
65. Tossman U, Delin A, Eriksson LS, Ungerstedt U. Brain cortical amino acids measured by intracerebral dialysis in portacaval shunted rats. Neurochem Res 12:265-270, 1987.
66. Butterworth RF. Evidence that hepatic encephalopathy results from a defect of glutamatergic synaptic regulation. Mol Neuropharmacol 2:229-232, 1992.
67. Swain MS, Bergeron M, Audet R, Blei AT, Butterworth RF. Monitoring of neurotransmitter amino acids by means of an indwelling cisterna magna catheter: A comparison of two rodent models of fulminant hepatic failure. Hepatology 16:1028-1035, 1992.
68. de Knegt RJ, Schalm SW, van der Rijt CC, Fekkes D, Dalm E, Hekking-Weyma I. Extracellular brain glutamate during acute liver failure and during acute hyperammonemia stimulatory acute liver failure: An experimental study based on in vivo brain dialysis. J Hepatol 20:19-26, 1994.
69. Michalak A, Rose C, Butterworth J, Butterworth RF. Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure. Hepatology 24:908-913, 1996.
70. Bender AS, Norenberg MD. Effects of ammonia on L-glutamate uptake in cultured astrocytes. Neurochem Res 21:567-573, 1996.
71. Rothstein JD, Martin L, Levey AI, Dykes-Horberg M, Jin L, Wu D, Nash N, Kuncl RW. Localization of neuronal and glial glutamate transporters. Neuron 13:713-772, 1994.
72. Norenberg. MD, Huo Z, Neary JT, Roig-Cantesano A. The glial glutamate transporter in hyperammonemia and hepatic encephalopathy: Relation to energy metabolism and glutamatergic neurotransmission. Glia 21:124-133, 1997.
73. Ferenci P, Pappas SC, Munson PJ, Jones EA. Changes in glutamate receptors on synaptic membranes associated with hepatic encephalopathy or hyperammonemia in the rabbit. Hepatology 4:25-29, 1984.
74. 3H-glutamate binding sites in rat brain following portacaval anastomosis. J Neurochem 55:386, 1990.
75. 3H-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid binding in a spontaneous canine model of chronic hepatic encephalopathy. J Neurochem 56:1881-1888, 1991.
76. 3H]5-fluorowillardiine in the brains of rats with acute liver failure. Hepatology 25:631-635, 1997.
77. Bergeron M, Reader TA, Layrargues GP, Butterworth RF. Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurochem Res 14:853-859, 1989.
78. Young SN, Lal S, Feldmuller F, Aranoff A, Martin JB. Relationships between tryptophan in serum and CSF and 5-hydroxyindoleacetic acid in CSF of man: Effects of cirrhosis of the liver and probenecid administration. J Neurol Neurosurg Psychiatry 38:322-330, 1975.
79. Bengtsson F, Bugge M, Johansen KH, Butterworth RF. Brain tryptophan hydroxylation in the portacaval shunted rat: A hypothesis for the regulation of serotonin turnover in vivo. J Neurochem 56:1069-1074, 1991.
80. Bergeron M, Swain MS, Reader TA, Grondin L, Butterworth RF. Effect of ammonia on brain serotonin metabolism in relation to function in the portacaval-shunted rat. J Neurochem 55:222-229, 1990.
81. Michalak A, Rose C, Buu PN, Butterworth R. Evidence for altered central noradrenergic function in experimental acute liver failure in the rat. Hepatology 27:362-368, 1998.
82. Bergqvist P, Heyes MP, Apelqvist G, Butterworth RF, Bengtsson F. Brain extracellular quinolinic acid in chronic experimental hepatic encephalopathy as assessed by in vivo microdialysis: Acute effects of L-tryptophan. Neuropsychopharmacology 15:382-389, 1996.
83. B in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Brain Res 621:349-352, 1993.
84. Apelqvist G, Bergqvist PB, Larsson B, Bugge M, Bengtsson F. Regional brain serotonin receptor changes in portacaval-shunted rats. Acta Physiol Scand 162:509-516, 1998.
85. Yurdaydin C, Herneth AM, Puspok A, Steindl P, Singer E, Ferenci P. Modulation of hepatic encephalopathy in rats with thioacetamide-induced acute liver failure by serotonin antagonists. Eur J Gastroenterol Hepatol 8:667-671, 1996.
86. Holm E, Jacobs S, Kortsik C, Leweling H, Fischer B. Failure of selective serotonin re-uptake inhibition to worsen the mental state of patients with subclinical hepatic encephalopathy. In: Soeters PB, Wilson JH, Meijer AJ, Holm E, Eds. Advances in Ammonia Metabolism and Hepatic Encephalopathy. Amsterdam: Elsevier, pp474-486, 1988.
87. Vorobioff J, Garcia-Tsao G, Groszmann R, Aceves G, Picabea E, Villavicencio R, Hernandez-Ortiz J. Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertensive patients. Hepatology 9:88-91, 1989.
88. Bergeron M, Swain MS, Reader TA, Butterworth RF. Increased mesocortical dopaminergic function following ammonia administration to rats with portacaval anastomosis. Neurochem Res 10:79-86, 1995.
89. 2 receptor density in hepatic encephalopathy. Neurosci Lett 162:192-196, 1993.
90. Hadesman R, Wiesner RH, Go VL, Tyce GM. Concentrations of 3,4-dihydroxyphenylalanine and catecholamines and metabolites in brain in an anhepatic model of hepatic encephalopathy. J Neurochem 65:1166-1175, 1995.
91. Murakami N, Saito K, Kato T, Nakamura T, Moriwaki H, Muto Y. Changes in brain monoamine metabolism in rats with acute ischemic hepatic failure under artificial cardiopulmonary management. Gastroenterol Jpn 27:191-198, 1992.
92. Yurdaydin C, Hortnagl H, Steindl P, Zimmermann C, Pifl C, Singer EA, Roth E, Ferenci P. Increased serotoninergic and noradrenergic activity in hepatic encephalopathy in rats with thioacetamide-induced acute liver failure. Hepatology 12:695-700, 1990.
93. McKinzie SL, Hammond DL, Grabau C, Tyce GM. Releases of norepinephrine and dopamine in ventriculocisternal perfusions in hepatectomized and laparotomized rats. J Neurochem 66:569-578, 1996.
94. Anderson B. A proposed theory for the encephalopathies of Reye's syndrome and hepatic encephalopathy. Med Hypotheses 15:415-420, 1984.
95. Schafer DF, Pappas SC, Brody LE, Jacobs R, Jones EA. Visual evoked potentials in a rabbit model of hepatic encephalopathy. I. Sequential changes and comparisons with drug-induced comas. Gastroenterology 86:540-545, 1984.
96. Basile AS, Jones EA, Skolnick P. The pathogenesis and treatment of hepatic encephalopathy: Evidence for the involvement of benzodiazepine receptor ligands. Pharmacol Rev 43:27-71, 1991.
97. Schafer DF, Jones EA. Hepatic encephalopathy and the γ-aminobutyric acid system. Lancet 1:18-20, 1982.
98. Schafer DF, Fowler JM, Munson PJ, Thakur AK, Waggoner JG, Jones EA. γ-Aminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic failure. J Lab Clin Med 102:870-880, 1983.
99. Roy S, Layrargues GP, Butterworth RF, Huet PM. Hepatic encephalopathy in cirrhotic and portocaval-shunted dogs: Lack of changes in brain GABA uptake, brain GABA levels, and brain glutamic acid decarboxylase activity and brain postsynaptic GABA receptors. Hepatology 8:845-849, 1988.
100. A receptor complex in an experimental model of encephalopathy: Evidence for elevated levels of an endogenous benzodiazepine receptor ligand. J Neurochem 53:1057-1063, 1989.
101. Olasmaa M, Rothstein JD, Guidotti A, Weber RJ, Paul SM, Spector S, Zeneroli ML, Baraldi M, Costa E. Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy. J Neurochem 55:2015-2023, 1990.
102. Layrargues GP, Butterworth RF. Efficacy of Rol5-1788 in cirrhotic patients with hepatic coma: Results of a randomized, double-blind placebo-controlled crossover trial. Hepatology 16:311, 1992.
103. Butterworth RF, Wells J, Layrargues GP. Detection of benzodiazepines in hepatic encephalopathy (reply). Hepatology 21:605, 1995.
104. Laidlaw J, Read AE, Sherlock S. Morphine tolerance in hepatic cirrhosis. Gastroenterology 40:389-396, 1961.
105. Salomon F, Beaubemard C, Thangapregassam MJ, Grange D, Bismuth H. Encéphalopathie hépatique expérimentale. II-Étude de la réaction à la douleur chez le rat avec anastomose porto-cave. Biol Gastroenterol (Paris) 9:105-108, 1976.
106. Thorton JR, Losowsky MS. Plasma methionine enkephalin concentration and prognosis in primary biliary cirrhosis. Br Med J 297:1241-1242, 1988.
107. Zeneroli ML, Baraldi M, Ventura E, Zanoli P, Vezzeli C, Russo AM. β-Endorphin and opiate receptor changes in acute and chronic models of hepatic encephalopathy. In: Butterworth RF, Layrargues GP, Eds. Hepatic Encephalopathy: Pathophysiology and Treatment. Clifton, NJ: Humana Press Inc., pp455-466, 1988.
108. Panerai AE, Salerno F, Baldissera F, Martini A, Di Giulio AM, Mantegazza P. Brain β-endorphin concentrations in experimental chronic liver disease. Brain Res 247:188-190, 1982.
109. Khachaturian H, Lewis ME, Schafer MK, Watson SJ. Anatomy of the CNS opioid systems. Trends Neurol Sci 10:111-119, 1985.
110. Martin JR, Porchet H, Buhler R, Bircher J. Increased ethanol consumption and blood ethanol levels in rats with portacaval shunts. Am J Physiol 248:G287-G292, 1985.
111. De Waele JP, Audet RM, Rose C, Butterworth RF. The portacavalshunted rat: A new model for the study of the mechanisms controlling voluntary ethanol consumption and ethanol dependence. Alcohol Clin Exp Res 21:305-310, 1997.
112. De Waele JP, Audet RM, Leong DK, Butterworth RF. Portacaval anastomosis results in region-selective changes of β-endorphin content and of μ and δ opioid receptor densities in rat brain. Hepatology 24:895-901, 1996.
113. 3H-PK11195 in rat brain following portacaval anastomosis. Brain Res 585:295-298, 1992.
114. 3H-PK11195 in rats following portacaval anastomosis. Digest Dis Sci 39:1055-1063, 1994.
115. 3H-PK11195 in congenital ornithine transcarbamylase deficient sparse-fur mouse. Pediatr Res 34:777-780, 1993.
116. Ducis I, Norenberg LO, Norenberg MD. Effect of ammonium chloride on the astrocyte benzodiazepine receptor. Brain Res 493:362-365, 1989.
117. 3H-PK11195. Neurosci Lett 177:35-38, 1994.
118. 3H-PK 11195. Neurosci Lett 271:5-8, 1999.
119. Zaman SH. Endogenous steroids and pathogenesis of hepatic encephalopathy. Lancet 336:573-574, 1990.
120. Costa E, Guidotti A. Diazepam binding inhibitor (DBI): A peptide with multiple biological actions. Life Sci 49:325-344, 1991.
121. Papadopoulos V. Peripheral-type benzodiazepine/diazepam binding inhibitor receptor: Biological role in steroidogenic cell function. Endocrine Rev 14:222-240, 1993.
122. Puia G, Santi MR, Vicini S, Pritchett DB, Seeburg PH, Costa E. Differences in the negative allosteric modulation of GABA receptors elicited by 4'-chlorodiazepam and by a β-carboline-3-carboxylate ester: A study with natural and reconstituted receptors. Proc Natl Acad Sci U S A 86:7275-7279, 1989.
123. Majewska MD, Schwartz RD. Pregnenolone-sulfate: An endogenous antagonist of the γ-aminobutyric acid receptor complex in brain? Brain Res 404:355-360, 1987.
124. Majewska MD, Mienville J-M, Vicini S. Neurosteroid pregnenolone sulfate antagonizes electrophysiological responses to GABA in neurons. Neurosci Lett 90:279-284, 1988.
125. Gee KW, Bolger MB, Brinton RE, Coirini H, McEwen BS. Steroid modulation of the 128 ride ionophore in rat brain: Structure activity requirements, regional dependence, and mechanism of action. J Pharmacol Exp Ther 246:803-812, 1988.
126. Majewska MD. Neurosteroids: Endogenous bimodal modulators of the GABA receptor: Mechanism of action and physiological significance. Prog Neurobiol 38:379-395, 1992.
127. Paul SM, Purdy RH. Neuroactive steroids. FASEB J 6:2311-2322, 1992.
128. Bender AS, Norenberg MD. Effect of benzodiazepines and neurosteroids on ammonia-induced swelling in cultured astrocytes. J Neurosci Res 54:673-680, 1998.
129. Garcia-Segura LM, Luquin S, P‡rducz A, Naftolin F. Gonadal hormone regulation of glial fibrillary acidic protein immunoreactivity and glial ultrastructure in the rat neuroendocrine hypothalamus. Glia 10:59-69, 1994.
130. Jung-Testas I, Renoir M, Bugnard H, Greene GL, Baulieu E-E. Demonstration of steroid hormone receptors and steroid action in primary cultures of rat glial cells. J Steroid Biochem Mol Biol 41:621-631, 1992.
131. Bologa L, Sharma J, Roberts E. Dehydroepiandrosterone and its sulfated derivative reduce neuronal death and enhance astrocytic differentiation in brain cell cultures. J Neurosci Res 17:225-234, 1987.
132. Garcia-Estrada J, Del Rio JA, Luquin S, Soriano E, Garcia-Segura LM. Gonadal hormones downregulate reactive gliosis and astrocyte proliferation after a penetrating brain injury. Brain Res 628:271-278, 1993.
133. Norenberg MD, Itzhak Y, Bender AS. The peripheral benzodiazepine receptor and neurosteroids in hepatic encephalopathy. In: Felipo V, Grisol'a S, Eds. Advances in Cirrhosis, Hyperammonemia, and Hepatic Encephalopathy. New York: Plenum Press, pp95-111, 1997.
134. Rothstein JD, McKhann G, Guarneri P, Barbaccia ML, Guidotti A, Costa E. Hepatic encephalopathy and cerebrospinal fluid content of diazepam binding inhibitor (DBI). Ann Neurol 26:57-62, 1989.
135. Costa E, Guidotti A. Diazepam Binding Inhibitor (DBI): A peptide with multiple biological actions. Life Sci 49:325-344, 1991.
136. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: A role for nitric oxide. Lancet 337:776-778, 1991.
137. 3H]arginine uptake in brain following portacaval anastomosis. J Neurochem 65:677-681, 1995.
138. Rao VL, Audet RM, Butterworth RF. Increased neuronal nitric oxide synthase expression in brain following portacaval anastomosis. Brain Res 765:169-172, 1977.
139. Kosenko E, Kaminsky Y, Kaminsky A, Valencia M, Lee L, Hermenegildo C, Felipo V. Superoxide production and antioxidant enzymes in ammonia intoxication in rats. Free Rad Res 27:637-644, 1997.
140. Norenberg MD, Itzhak Y. Acute liver failure and hyperammonemia increase nitric oxide synthase in mouse brain. Soc Neurosci Abst 21:869, 1995.
141. Kosenko E, Kaminsky Y, Grau E, Misana MD, Grisolia S, Felipo V. Nitroarginine, an inhibitor of nitric oxide synthetase, attenuates ammonia toxicity and ammonia-induced alterations in brain metabolism. Neurochem Res 20:451-456, 1995.
142. Kosenko E, Kaminsky Y, Lopata O, Muravyov N, Kaminsky A, Hermenegildo C, Felipo V. Nitroarginine, an inhibitor of nitric oxide synthase, prevents changes in superoxide radical and antioxidant enzymes induced by ammonia intoxication. Metab Brain Dis 13:29-41, 1998.
143. Katchman AN, Hershkowitz N. Nitric oxide modulates synaptic glutamate release during anoxia. Neurosci Lett 228:50-54, 1997.
144. Albrecht J, Hilgier W, Rafalowska U. Activation of arginine metabolism to glutamate in rat brain synaptosomes in thioacetamide-induced hepatic encephalopathy: An adaptive response? J Neurosci Res 25:125-130, 1990.
145. 3H-nitroarginine into rat brain synaptosomes. J Neurochem 68:337-343, 1997.
146. Hazell AS, Norenberg MD. Ammonia and manganese increase arginine uptake in cultured astrocytes. Neurochem Res 23:869-873, 1998.
147. Spranger M, Schwab S, Desiderata S, Bonmann E, Krieger D, Fandrey J. Manganese augments nitric oxide synthesis in murine astrocytes: A new pathogenetic mechanism in manganism? Exp Neurol 149:277-283, 1998.
148. Mans AM, DeJoseph MR, Hawkins RA. Metabolic abnormalities and grade of encephalopathy in acute hepatic failure. J Neurochem 63:1829-1838, 1994.
149. Mendenhall CL, Rouster S, Marshall L, Weesner R. A new therapy for portal systemic encephalopathy. Am J Gastroenterol 81:540-543, 1986.
150. Kircheis G, Quack G, Erbler H. L-ornithine-L-aspartate in the treatment of hyperammonemia and hepatic encephalopathy. In: Conn HO, Bircher J, Eds. Hepatic Encephalopathy: Syndromes and Therapies. Bloomington, IL: Medi-Ed Press, pp373-383, 1994.
151. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, Hendricks R, Kruger B, Kuklinski B, Meister H, Otto HJ, Rink C, Rosch W, Stauch S. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled, double-blind study. Hepatology 25:1351-1360, 1997.
152. Rose C, Michalak P, Pannunzio P, Therrien G, Quack G, Kircheis G, Butterworth RF. L-Ornithine-L-aspartate in experimental portalsytemic encephalopathy: Therapeutic efficacy and mechanism of action. Metab Brain Dis 12:147-157, 1998.
153. Themen G, Butterworth J, Rose C, Butterworth RF. Protective effect of L-carnitine in ammonia-precipitated encephalopathy in portacavalshunted rats: Evidence for a central mechanism of action. Hepatology 25:551-556, 1997.
154. O'Conner JE, Costell M, Grisolia S. Protective effect of L-carnitine on hyperammonemia. FEBS Lett 30:331-334, 1984.
155. Rudman D, Sewell CW, Ansley JD. Deficiency of carnitine in cachectic cirrhotic patients. J Clin Invest 60:716-723, 1977.
156. Hearn TJ, Coleman AE, Lai JC, Griffith OW, Cooper AJ. Effect of orally administered L-carnitine on blood ammonia and L-carnitine concentrations in portacaval-shunted rats. Hepatology 10:822-828, 1989.
157. Herneth AM, Püspök A, Steindl P, Yurdaydin C, Ferenci P. The influence of serotonin antagonists on hepatic encephalopathy in rats with thioacetamide induced liver failure. In: Capocaccia L, Merli M, Riggio O, Eds. Advances in Hepatic Encephalopathy and Metabolic Nitrogen Exchange. Boca Raton, FL: CRC Press, pp254-258, 1995.
158. Krulich L, McCann SM, Mayfield MA. On the mode of the prolactin release-inhibiting action of the serotonin blockers metergoline, methysergide, and cyproheptadine. Endocrinology 108:1115-1124, 1981.
159. Marcaida G, Felipo V, Hermenegildo C, Minana MD, Grisolia S. Acute ammonia toxicity is mediated by the NMDA type of glutamate receptor. FEBS Lett 296:67-68, 1992.
160. Vogels BA, Maas MA, Daaluisen J, Quack G, Chamuleau RA. Memantine, a noncompetitive NMDA-receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats. Hepatology 25:820-827, 1997.
161. Butterworth RF. Hepatic encephalopathy and brain edema in acute hepatic failure: Does glutamate play a role? Hepatology 25:1032-1034, 1997.